Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.29 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of trabectedin for the treatment of localized (non-metastatic) myxoid / round cell liposarcoma (malignant tumor derived from primitive or embryonal lipoblastic cells).

This is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), multicenter (when more than one hospital or medical school team work on a medical research study) study of trabectedin for the treatment of localized myxoid / round cell liposarcoma (MRCL). Trabectedin will be given at 1.5 milligram per meter square (mg/m\^2) over a 24-hour intravenous (iv) infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles along with dexamethasone 20 mg iv which will be given within 30 minutes before start of each trabectedin iv infusion. Participants whose myxoid/round cell liposarcoma (MRCL) do not progress at the end of the neoadjuvant treatment will be followed every 6 weeks for disease progression or until 6 months post definitive surgery, in the absence of unacceptable toxicity and/or disease progression. Efficacy will be assessed by determining the pathologic Complete Response (pCR) rate assessed in the tumor surgical specimen by a central pathology review. Participants' safety will be monitored throughout the trial.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Liposarcoma,Myxoid

Interventions

TrabectedinDRUG

Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.

DexamethasoneDRUG

Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathological diagnosis of myxoid / round cell liposarcoma (MRCL) and availability of pathology specimens for central review and pharmacogenomic studies * Clinical evidence of locally advanced (Stage III), non-metastatic tumor, including locally recurring disease after initial surgery * Measurable disease (by Response Evaluation Criteria In Solid Tumors \[RECIST\]) * No prior chemotherapy or radiation (except for adjuvant post-operative radiotherapy) * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 Exclusion Criteria: * Known hypersensitivity to any of the components of the trabectedin intravenous (iv) formulation or dexamethasone * Pregnant or lactating women and women of reproductive potential who are not using effective contraceptive methods * History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 5 years or longer * Known distant metastases * Other serious illnesses such as congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias

Locations (8)

Unnamed facility

Coeur d'Alene, Idaho, United States

Unnamed facility

Park Ridge, Illinois, United States

Unnamed facility

Iowa City, Iowa, United States

Unnamed facility

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Percentage of Participants With Pathological Complete Response (pCR)

Complete pathological response is complete disappearance of the tumor tissue up to the molecular level.

Time frame: Every 6 weeks until disease progression (up to Week 33) or 6 months post surgery.

Secondary Outcomes

Percentage of Participants With Objective Tumor Response Based on Response Evaluation Criteria In Solid Tumors (RECIST)

The objective tumor response is defined as the percentage of participants achieving partial response (PR) on tumor response assessed by RECIST. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame: Every 6 weeks until disease progression (up to Week 33) or 6 months post surgery.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.